Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor-positive/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy

[1] Gerdes J(1991)Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67 Am J Pathol 138 867-873

[2] Li L(1983)Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 13-20

[3] Schlueter C(2005)Proliferation marker Ki-67 in early breast cancer J Clin Oncol 23 7212-7220

[4] Duchrow M(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[5] Wohlenberg C(2011)Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group J Natl Cancer Inst 103 1-9

[6] Gerlach C(2010)Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 174-183

[7] Gerdes J(2002)Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer Breast Cancer Res Treat 71 161-170

[8] Schwab U(2001)Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer Clin Cancer Res 7 1716-1723

[9] Lemke H(1996)Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis Int J Cancer 69 135-141

[10] Stein H(2008)Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole J Clin Oncol 26 5569-5575

[1] Gerdes J(1991)Immunobiochemical and molecular biologic characterization of the cell proliferation-associated nuclear antigen that is defined by monoclonal antibody Ki-67 Am J Pathol 138 867-873

[2] Li L(1983)Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation Int J Cancer 31 13-20

[3] Schlueter C(2005)Proliferation marker Ki-67 in early breast cancer J Clin Oncol 23 7212-7220

[4] Duchrow M(2007)Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12,155 patients Br J Cancer 96 1504-1513

[5] Wohlenberg C(2011)Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group J Natl Cancer Inst 103 1-9

[6] Gerlach C(2010)Ki67 in breast cancer: prognostic and predictive potential Lancet Oncol 11 174-183

[7] Gerdes J(2002)Prognostic significance of tumor cell proliferation analyzed in fine needle aspirates from primary breast cancer Breast Cancer Res Treat 71 161-170

[8] Schwab U(2001)Measures of cell turnover (proliferation and apoptosis) and their association with survival in breast cancer Clin Cancer Res 7 1716-1723

[9] Lemke H(1996)Relationship between p53 gene abnormalities and other tumour characteristics in breast-cancer prognosis Int J Cancer 69 135-141

[10] Stein H(2008)Prognostic and predictive value of centrally reviewed Ki-67 labeling index in postmenopausal women with endocrine-responsive breast cancer: results from Breast International Group Trial 1–98 comparing adjuvant tamoxifen with letrozole J Clin Oncol 26 5569-5575